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It is not well established whether the incident outcomes of the
clinical high-risk (CHR) syndrome for psychosis are diagnostically specific for psychosis or whether CHR patients
also are at elevated risk for a variety of nonpsychotic disorders. We collected 2 samples (NAPLS-1, PREDICT) that
contained CHR patients and a control group who responded
to CHR recruitment efforts but did not meet CHR criteria on interview (help-seeking comparison patients [HSC]).
Incident diagnostic outcomes were defined as the occurrence
of a SIPS-defined psychosis or a structured interview diagnosis from 1 of 3 nonpsychotic Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
groups (anxiety, bipolar, or nonbipolar mood disorder), when
no diagnosis in that group was present at baseline. Logistic
regression revealed that the CHR vs HSC effect did not
vary significantly across study for any emergent diagnostic
outcome; data from the 2 studies were therefore combined.
CHR (n = 271) vs HSC (n = 171) emergent outcomes were:
psychosis 19.6% vs 1.8%, bipolar disorders 1.1% vs 1.2%,
nonbipolar mood disorders 4.4% vs 5.3%, and anxiety disorders 5.2% vs 5.3%. The main effect of CHR vs HSC was
statistically significant (OR = 13.8, 95% CI 4.2–45.0, df =
1, P < .001) for emergent psychosis but not for any emergent
nonpsychotic disorder. Sensitivity analyses confirmed these
findings. Within the CHR group emergent psychosis was
significantly more likely than each nonpsychotic DSM-IV
emergent disorder, and within the HSC group emergent
psychosis was significantly less likely than most emergent
nonpsychotic disorders. The CHR syndrome is specific as a
marker for research on predictors and mechanisms of developing psychosis.

Key words: validity/bipolar disorder/nonbipolar mood
disorder/anxiety disorder
Introduction
For the past 30 years efforts have been made to identify signs of psychosis as early as possible,1–6 with the
ideal goal of identifying individuals at risk for psychosis
before symptoms fully manifest. The hope is that early
identification may lead to faster clinical engagement
that delays or prevents transition to full-blown cases of
this possibly devastating disease. There is evidence that
early intervention in patients with established psychosis
leads to improved outcomes,7–9 and preliminary evidence
that intervening before the onset of frank psychosis may
reduce subsequent disease burden.10–12
Centers specializing in early psychosis detection
typically use structured diagnostic instruments such as
the SIPS13 or Comprehensive Assessment of At-Risk
Mental States.14 These instruments are administered
by specially trained personnel and examine symptom
severity in multiple domains of psychotic behavior
and general mental health functioning in order to classify those likely to be at clinical high risk (CHR) for
eventual conversion to psychosis. Use of the SIPS carried a low rate of endorsement for the most common
CHR syndrome in an epidemiologic sample,15 and use
of these instruments carries a positive predictive value
of 32% for conversion to psychosis at 3 years in clinical samples of help-seeking CHR subjects assessed by
high-risk services.16
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While structured rating instruments provide a useful
risk assessment for conversion to psychosis, there has
been concern about whether clinical outcomes in CHR
patients are specific to psychosis, or whether patients so
identified are generally at increased risk for many psychiatric disorders.17–19 This concern arises in part because
most CHR subjects do not go on to develop full psychosis,16 and in part because two-thirds or more of CHR
subjects have other comorbid Axis I diagnoses at ascertainment,20–25 primarily affective and anxiety disorders,
that contribute to the functional deficits21 and psychopathologic symptoms21 seen in CHR samples.
Whether CHR points specifically to risk for future psychosis vs to nonspecific deterioration in mental health
has clear research and policy implications. If the CHR
designation offers no specific prognosis with regard to
psychosis, then making a CHR assessment may be of little additional help beyond general mental health screening, because it would not differentiate a need for specialty
treatment programs aimed at psychosis. Moreover,
research studies of CHR would not be investigating risk
factors or biomarkers that are specific for psychosis but
rather general risk factors for a mixture of mental disorders. In fact, a recent study found that affective/anxiety
comorbidity in CHR patients was associated with lower
gray matter volumes in anterior cingulate than in CHR
patients without comorbidity.26
Understanding whether a CHR designation specifically
delineates risk for developing psychosis necessarily relies
on comparing incident rates of psychosis vs incident rates
of other classes of psychiatric disorders. Unfortunately,
however, while baseline comorbidity of psychiatric disorders in CHR patients is already well described, only
1 study has examined incident nonpsychotic diagnostic
outcomes in CHR patients,27 and we are aware of none
that have directly compared such outcomes in CHR with
those from psychiatric patients who did not meet CHR
criteria. We therefore conducted the present analyses
using data from 2 large naturalistic samples.
Method
We report data from 2 cohorts of CHR syndrome patients
that each also included a comparison group of patients
who did not meet criteria for CHR syndrome or psychosis. The comparison patients are termed “help-seeking
comparison subjects” (HSCs). Both CHR and HSC
patients responded to CHR recruitment efforts, passed
a phone screen designed to eliminate those who had no
target symptoms or were obviously psychotic, and were
invited to and underwent SIPS evaluation. CHR patients
met SIPS criteria at evaluation, and HSC patients did
not. These patient groups have been shown to differ on
rate of conversion to psychosis, positive and negative
symptoms, current functioning, mood disorder comorbidity, and family history.25 A recent meta-analysis of 11

studies confirms the higher risk of psychosis in the CHR
patients vis-a-vis HSC, with an OR estimate of 20.2.28
The present 2 cohorts were the first sample of the North
American Prodromal Longitudinal Study (NAPLS-1)
and the PREDICT study. Our newer NAPLS-2 sample29
did not follow HSCs or collect detailed baseline data on
them. Methods for NAPLS-130 and PREDICT31 have
been reported previously.
Subjects
NAPLS-1 merged data collected at 8 sites on 303 CHR
syndrome and 135 HSC patients enrolled between early
1998 and early 2005 and for whom data were available
for at least 1 follow-up timepoint (supplementary figure 1).25 The dataset includes interim data from the first
44 CHR and 24 HSC qualifying patients enrolled in the
PREDICT study. For the present analyses these subjects
are included in the PREDICT sample rather than in the
NAPLS-1 sample, because when the NAPLS-1 dataset
was closed, PREDICT follow-up was still ongoing. Of
the remaining 259 CHR and 111 HSC NAPLS-1 patients,
160 (62%) and 100 (90%), respectively, underwent structured diagnostic interviews for Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
Axis I diagnoses at baseline and also at 1 or more followup evaluations. Among the HSC patients, 69 (69.0%) had
no positive symptoms in the SIPS CHR severity range at
baseline, and 31 (31.0%) had symptoms that met severity
criteria but not worsening or frequency criteria.
PREDICT was conducted at 3 of the NAPLS-1 sites
(University of North Carolina, University of Toronto,
and Yale University), and enrolled 151 CHR syndrome
and 86 HSC patients between late 2003 and early 2008
who contributed follow-up data (supplementary figure 1). Of these, 111 CHR (74%) and 71 HSC (83%) also
underwent structured diagnostic interviews for DSM-IV
Axis I diagnoses at baseline and at 1 or more follow-up
evaluations. Among the HSC patients, 34 (47.9%) had no
positive symptoms in the CHR severity range at baseline,
and 37 (52.1%) had symptoms that met severity criteria
but not worsening or frequency criteria.
Data on the recruitment sources in these 2 studies
were not collected systematically, but recruitment methods were broadly similar to those reported in the later
NAPLS-2 sample, where approximately 15% of both
CHRs and HSCs were referred by the school/community
sector, roughly 40% of CHRs and 35% of HSCs were
referred by the health/mental health sector, and about
45% of CHRs and 50% of HSCs were referred by self,
family/friends, or other.29 Inclusion and exclusion criteria
were also similar in the 2 studies. One exception is that
CHR and HSC patients in PREDICT could not enroll
if they had received antipsychotic medication in the past
week and there was a clinical need for the antipsychotic
to continue.
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Assessments
Each site in both studies utilized the Structured Interview
for Psychosis-risk Syndromes (SIPS) to determine
whether psychosis and CHR syndrome criteria were
met.13 Reliability of the SIPS has been reported previously32–35 and was established in these studies for all sites.30
Structured assessment of DSM-IV Axis-I diagnoses in
NAPLS-1 varied somewhat within and across sites,25 with
most subjects receiving versions of the Structured Clinical
Interview for DSM-IV (SCID)36 or the Schedule for
Affective Disorder and Schizophrenia for School-Aged
Children (K-SADS).37 The Comprehensive Assessment
of Symptoms and History38 was used for some subjects. PREDICT employed the SCID-NP39 for subjects
16 and older and the K-SADS37 for those 15 and under.
Follow-up assessments were available at 6-month intervals in both studies, out to 30 months in NAPLS-1 and to
48 months in PREDICT. Only follow-up timepoints with
DSM-IV diagnostic interviews were permitted to contribute to data analysis.
Depressive and anxiety comorbidities are the most
common in CHR patients,21 and we felt it important to
distinguish between bipolar and nonbipolar disorders.
Accordingly, for both studies nonpsychotic DSM-IV Axis-I
diagnoses were classified into 3 groups: bipolar disorders
(DSM-IV nonpsychotic bipolar I disorder, bipolar disorder NOS, bipolar II disorder, and cyclothymic disorder),
nonbipolar mood disorders (DSM-IV nonpsychotic major
depressive disorder, dysthymic disorder, depressive disorder
not otherwise specified [NOS], and mood disorder NOS),
and anxiety disorders (panic disorder with or without agoraphobia, generalized anxiety disorder, agoraphobia without panic disorder, social phobia, specific phobia, obsessive
compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, and anxiety disorder NOS).
Emergence of psychosis, or “incident psychosis,”
was defined by SIPS criteria as previously described.25
Emergent nonpsychotic disorders was defined among
subjects who did not convert to psychosis as the emergence at any time during follow-up of a DSM-IV diagnosis from 1 of the 3 nonpsychotic groups, when no
diagnosis in that DSM-IV group was present at baseline.
Data on psychotropic medication use at baseline were
collected in both studies and were reported previously for
NAPLS-1.40–42 Duration of CHR syndrome data was collected from fields in the SIPS. When more than 1 CHR
syndrome was present, the longer duration was used.
Current functioning at baseline was assessed in both
studies with the Global Assessment of Functioning43
included in the SIPS.
Statistical Methods
Analyses were conducted using SPSS version 19. P values
< .05 were considered statistically significant. Baseline
characteristics were compared using Student’s t tests and
1068

χ2. In 1 case, 2 incident nonpsychotic disorders emerged
at the same timepoint (nonbipolar mood disorder and
anxiety disorder in a PREDICT CHR subject). In order
to permit initial omnibus multinomial regression and
2 × 5 χ2 analyses of incident outcome, the nonbipolar
mood disorder was treated as trumping the anxiety disorder. In the remaining analyses this “trumping” rule was
not applied. The multinomial regression incorporated
terms for baseline diagnosis (CHR vs HSC) and study
(NAPLS-1 vs PREDICT).
Logistic regression was used to compare disorderspecific incident outcome rates, incorporating the same
terms as for the multinomial regression, with post hoc 2
× 2 χ2 analyses. Product terms were added to the logistic models to test interaction effects between study and
baseline CHR vs HSC diagnosis; when models either
would not converge or did not reach a level of statistical significance, interaction terms were omitted. When
baseline characteristics differed significantly across CHR
and HSC groups in either study, effects of inclusion of
terms for these characteristics were evaluated in models
showing significant independent CHR vs HSC effects.
Effects of baseline characteristics were examined similarly in models showing significant effects of study. The
primary analyses expressed rates of incident disorder as
number of emergent cases divided by number of all cases.
Because rates of baseline disorders varied across CHR
vs HSC (table 1), sensitivity analyses were conducted
excluding patients with baseline disorder and expressing
rates of incident disorder as number of emergent cases
divided by number of cases not excluded.
Because rates of baseline disorder varied across diagnosis, within group comparisons of emergent disorder
across diagnostic outcome were restricted to pairwise
analyses vs emergent psychosis and to analyses excluding
baseline cases of comparator disorder. These comparisons employed Cochran’s Q.
Results
Baseline Characteristics
Table 1 compares CHR and HSC samples on baseline characteristics. CHR patients had higher Scale of
Psychosis-risk Symptoms (SOPS) total, positive, and
general symptom scores and higher use rates of any
psychotropic than HSC in both studies. In NAPLS-1,
CHR patients were also older and had lower functioning scores and higher SOPS negative and disorganization
scores, higher rates of antipsychotic and antidepressant
use, and higher rates of any mood/anxiety disorder and
nonbipolar mood disorder comorbidity than HSC. CHR
samples differed across study at baseline on age (1.5 years
younger in NAPLS-1), functioning (lower in NAPLS-1),
SOPS scores (total, negative, and disorganized all higher
in NAPLS-1), and antipsychotic and mood stabilizer use
(both higher in NAPLS-1). CHR syndrome duration
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Table 1. Baseline Characteristics of NAPLS-1 and PREDICT Samples
NAPLS-1

PREDICT

Measure

CHR (n = 160)a

HSC (n = 100)b

CHR (n = 111)c

HSC (n = 71)d

Age
No. male
No. Caucasian
Parental education
Global functioning
CHR duration, dayse
SOPS total
SOPS positive
SOPS negative
SOPS disorganized
SOPS general
Any mood/anx disorder
DSM-IV bipolar
DSM-IV nonbipolar mood
DSM-IV anxiety
Any psychotropic
Antipsychotic
Antidepressant
Mood stabilizer
Stimulant
Benzodiazepine

18.1 ± 4.4g,j
92 (57.5%)
123 (76.9%)
5.58 ± 1.69
48.7 ± 11.6i,j
722 ± 1056i
36.6 ± 14.0i,j
11.2 ± 4.2i
11.6 ± 6.7f,i
6.3 ± 3.7i,j
7.9 ± 4.3i
122 (76.3%)i
4 (2.5%)
92 (57.5%)i
69 (43.1%)
77 (50.0%)g
33 (21.4%)g,i
55 (35.7%)f
9 (5.8%)f
8 (5.2%)
9 (5.8%)

15.7 ± 2.9i,j
64 (64.0%)
68 (68.0%)
5.89 ± 1.95
54.9 ± 11.9i
NA
22.5 ± 12.5i
4.0 ± 3.4i,k
9.9 ± 6.5f
3.4 ± 3.1h
5.4 ± 4.3i
52 (52.0%)i
0 (0.0%)
37 (37.0%)i
33 (33.0%)
32 (32.0%)g
8 (8.0%)g,f
23 (23.0%)f
1 (1.0%)
10 (10.0%)f
2 (2.0%)

19.6 ± 4.7g
60 (54.1%)
82 (73.9%)
6.00 ± 2.48
54.9 ± 12.5j
261 ± 298i
30.2 ± 11.3h,j
10.9 ± 3.1j
8.4 ± 5.7i
4.0 ± 2.6j
7.0 ± 4.0f
74 (66.7%)
0 (0.0%)
54 (48.6%)
46 (41.4%)
48 (43.2%)f
1 (0.9%)i
39 (35.1%)
1 (0.9%)f
5 (4.5%)
10 (9.0%)

19.3 ± 4.2j
37 (52.1%)
53 (74.6%)
5.56 ± 2.37
56.2 ± 11.8
NA
25.2 ± 13.4h
6.9 ± 4.3j,k
8.7 ± 6.0
3.9 ± 3.0
5.7 ± 4.2f
42 (59.2%)
0 (0.0%)
27 (38.0%)
22 (31.0%)
20 (28.2%)f
0 (0.0%)f
17 (23.9%)
0 (0.0%)
1 (1.4%)f
4 (5.6%)

Notes: CHR, clinical high risk; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SOPS, Scale of
Psychosis-risk Symptoms; NA, not applicable.
a
varied from 137–160 across measure other than CHR duration.
b
varied from 78–100 across measure.
c
n = 111 except for CHR duration.
d
varied from 70–71 across measure.
e
n = 55 for NAPLS-1 and 105 for PREDICT.
f
groups with these letters differ P < .05.
g/h
groups with these letters differ P < .01.
i/j/k
groups with these letters differ P < .001.

was not recorded systematically in NAPLS-1 but when
recorded was nearly 3 times as long as in PREDICT. HSC
samples differed at baseline on age (lower in NAPLS-1,
table 1), SOPS positive symptoms (higher in PREDICT),
and stimulant use (higher in NAPLS-1).
Incident Diagnoses
The multinomial regression for emergent disorder produced a highly significant model (χ2 = 67.4, df = 8, P <
.001), with highly significant main effects of baseline CHR
vs HSC diagnosis (χ2= 38.1, df = 4, P < .001). Multinomial
models including baseline CHR vs HSC diagnosis × study
product terms or restricted to either study would not converge due to zero cells. Main effects of study (NAPLS-1
vs PREDICT) were also highly significant (χ2= 29.3, df =
4, P < .001). Follow-up logistic models containing product terms testing interactions between CHR vs HSC and
study would either also not converge (anxiety and bipolar)
or did not reach a level of statistical significance (nonbipolar mood disorder); thus further analyses focused on
the merged samples (supplementary figure 1).

Logistic regression revealed that the significant effect
of CHR vs HSC diagnosis on emergent disorder was
accounted for by effects on emergent psychosis (19.6%
vs 1.8%, P < .001, figure 1 and supplementary table 1).
No significant effects of CHR vs HSC diagnosis were
observed for other emergent disorders (figure 1, supplementary table 2). Logistic regression further revealed that
CHR vs HSC rates for any emergent nonpsychotic disorder (ie, any of bipolar, nonbipolar mood, or anxiety) also
did not significantly differ, in the merged (supplementary
table 2) or NAPLS-1 (OR = 1.07, 95% CI 0.41 to 2.85)
or PREDICT (OR = 0.75, 95% CI 0.34 to 1.68) samples.
Significant main effects of study were seen for emergent
psychosis (NAPLS-1 higher) and for emergent anxiety
disorders (PREDICT higher.
Sensitivity analyses showed that the CHR vs HSC difference for incident psychosis continued to hold whether
analyses included or excluded subjects with each or any
baseline disorder from the model (all P’s < .001, supplementary table 1). Similarly, the lack of CHR vs HSC
differences for incident nonpsychotic disorders also continued to hold whether models included subjects with
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baseline disorder (as noncases of emergent disorder) or
excluded them (all P’s > .500, supplementary table 2).
Two-by-five and pairwise χ2 analyses (table 2) revealed
similar findings as the multinomial and logistic regression
models. CHR and HSC groups significantly differed only
on incident psychosis, and this difference was significant
in each study.

Fig. 1. Incident diagnostic outcomes in combined NAPLS-1
and PREDICT studies. CHR, clinical high risk (n = 271).
HSC, help-seeking comparison patients (n = 171). Models also
contain a term for study. Non-BP: nonbipolar. One subject with
simultaneous emergent anxiety and nonbipolar mood disorders
appears in both groups (see text). *CHR vs HSC comparison
OR = 13.8, 95% CI 4.2–45.0, df = 1, P < .001, no asterisk - n.s.,
(supplementary table 1).

Within group comparisons of incident disorder in the
merged CHR sample showed that emergent psychosis
was significantly more likely than emergent nonpsychotic
disorder for each of the 3 individual nonpsychotic classes
(table 3). Incident psychosis was not significantly more
likely, however, than any incident nonpsychotic disorder.
In the NAPLS-1 sample alone, findings were similar or
stronger than in the merged samples, and incident psychosis did occur significantly more frequently than any incident nonpsychotic disorder (supplementary table 3). In
the PREDICT sample alone, however, emergent psychosis
was significantly more likely than emergent nonpsychotic
disorder only for bipolar disorder (supplementary table 3).
Within group comparisons of emergent disorder in the
merged HSC sample showed that emergent psychosis was
significantly less likely than emergent nonbipolar mood
disorder, anxiety disorder, or any nonpsychotic disorder
(table 3). In the NAPLS-1 sample alone, findings were similar to those in the merged samples, except that there were no
cases of incident anxiety disorder (supplementary table 4).
In the PREDICT sample alone, emergent psychosis was
significantly less likely than emergent anxiety disorder and
any nonpsychotic disorder (supplementary table 4).
Potential Confounders
Entry of terms for global functioning, SOPS total, positive, negative, or disorganized symptoms, nonbipolar

Table 2. Emergent Diagnostic Outcomes by Baseline CHR Diagnosis in Each Study
Emergent Diagnostic Outcomes (%)
Study

Subjects (n)

Bipolar Disorder

Nonbipolar Mood

Anxiety Disorder

Psychosis

NAPLS-1

CHR (160)
HSC (100)
CHR (111)
HSC (71)

3 (1.9%)a
1 (1.0%)e
0 (0%)i
1 (1.4%)m

7 (4.4%)b
6 (6.0%)f
5 (4.5%)j
3 (4.2%)n

2 (1.3%)c
0 (0%)g
12 (10.8%)k
9 (12.7%)o

39 (24.3%)d
1 (1.0%)h
14 (12.6%)l
2 (2.8%)p

PREDICT

Notes: HSC, help-seeking comparison subject patients; Bipolar Disorder: nonpsychotic, bipolar mood disorder; Nonbipolar Mood:
nonpsychotic, nonbipolar mood disorder. The 1 subject with simultaneous emergent anxiety and nonbipolar mood disorders appears in
both columns (see text).
Between-baseline CHR diagnosis comparisons (P < .05 underlined).
2 × 5 analysis of incident disorder— CHR vs HSC overall: χ2 = 30.3 df = 4 P ≤ .001; CHR vs HSC in NAPLS-1: χ2 = 28.3 df = 4 P <
.001; CHR vs HSC in PREDICT: χ2 = 6.7 df = 4 P = .153.
Pairwise analyses of individual incident disorders— CHR vs HSC in NAPLS-1: a vs e χ2 = 0.3 df = 1 P = .577, b vs f χ2 = 0.3 df = 1
P = .559, c vs g χ2 = 1.3 df = 1 P = .262, d vs h χ2 = 25.8 df = 1 P < .001; CHR vs HSC in PREDICT: i vs m χ2 = 1.6 df = 1 P = .210, j vs
n χ2 = 0.0 df = 1 P = .929, k vs o χ2 = 0.1 df = 1 P = .701, l vs p χ2 = 5.2 df = 1 P = .023.
Pairwise analysis of any incident nonpsychotic disorder— CHR vs HSC overall: 28/271 (10.3%) vs 20/171 (11.7%), χ2 = 0.1 df = 1
P = .654; CHR vs HSC in NAPLS-1: 12/160 (8.1%) vs 7/100 (7.0%), χ2 = 0.0 df = 1 P = .880; CHR vs HSC in PREDICT: 16/111
(14.4%) vs 13/71 (18.3%), χ2 = 0.5 df = 1 P = .484.
Between-study pairwise comparisons (P < .05 underlined).
2 × 5 analysis of incident disorder— NAPLS-1 vs PREDICT overall: χ2 = 28.6 df = 4 P < .001; NAPLS-1 vs PREDICT in CHR:
χ2 = 18.5 df = 4 P < .001; NAPLS-1 vs PREDICT in HSC: χ2 = 14.6 df = 4 P = .006.
Pairwise analyses of individual incident disorders— NAPLS-1 vs PREDICT in CHR: a vs i χ2 = 2.1 df = 1 P = .147, b vs j χ2 = 0.0 df = 1
P = .959, c vs k χ2 = 12.2 df = 1 P < .001, d vs l χ2 = 5.7 df = 1 P = .016; NAPLS-1 vs PREDICT in HSC: e vs m χ2 = 0.1 df = 1 P = .807,
f vs n χ2 = 0.3 df = 1 P = .609, g vs o χ2 = 13.4 df = 1 P < .001, h vs p χ2 = 0.8 df = 1 P = .373.
Pairwise analysis of any incident nonpsychotic disorder— NAPLS-1 vs PREDICT overall: 19/260 (7.3%) vs 29/182 (15.9%), χ2 = 8.2 df =
1 P = .004; NAPLS-1 vs PREDICT in CHR: 12/160 (7.5%) vs 16/111 (14.4%), χ2 = 3.4 df = 1 P = .066; NAPLS-1 vs PREDICT in HSC:
7/100 (7.0%) vs 13/71 (18.3%), χ2 = 5.1 df = 1 P = .023.
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Table 3. Within Group Analyses Comparing Emergent Psychosis to Other Emergent Disorders
Merged CHR Sample

Emergent Disorder

Incidence Rates

Cochran’s Q

df

P value

Baseline bipolar excluded

Psychosis
Bipolar
Psychosis
Nonbipolar mood
Psychosis
Anxiety
Psychosis
Any mood/anxiety

52/267 (19.5%)
3/267 (1.1%)
30/125 (24.0%)
12/125 (9.6%)
36/156 (23.1%)
14/156 (9.0%)
19/75 (25.3%)
13/75 (17.3%)a

43.7

1

<.001

7.7

1

.005

9.7

1

.002

1.1

1

.289

Merged HSC Sample

Emergent Disorder

Incidence Rates

Cohran’s Q

df

P value

Baseline bipolar excluded

Psychosis
Bipolar
Psychosis
Nonbipolar mood
Psychosis
Anxiety
Psychosis
Any mood/anxiety

3/171 (1.8%)
2/171 (1.2%)
3/107 (2.8%)
9/107 (8.4%)
1/116 (0.9%)
9/116 (7.8%)
1/77 (1.3%)
15/77 (8.5%)b

0.2

1

.655

3.0

1

.083

6.4

1

.011

12.2

1

<.001

Baseline nonbipolar excluded
Baseline anxiety excluded
Any baseline mood/anxiety excluded

Baseline nonbipolar excluded
Baseline anxiety excluded
Any baseline mood/anxiety excluded

Notes: Nonbipolar, nonbipolar mood disorder; effect CHR vs HSC, - OR from logistic regression model including term for study.
a
Emergent cases do not sum to 3 + 13 + 16 = 32 for 2 reasons: (1) in 1 PREDICT CHR patient 2 emergent nonpsychotic disorders
appeared at the same time point (see text), and (2) unlike in the analyses above patients are considered emergent cases only if no disorder
is present at baseline.
b
Emergent cases do not sum to 2 + 9 + 10 = 21 for second reason above.

mood disorder, or baseline antipsychotic or antidepressant
each significantly improved the logistic regression model
for incident psychosis (supplementary table 5). Most
reduced the significance of the CHR vs HSC effect, which
nevertheless remained strong in all cases. Inclusion of
terms for other variables differing between CHR and HSC
samples in table 1 did not improve the model. With regard
to the study effect on emergent psychosis, the NAPLS-1 vs
PREDICT differences in table 1 each mediated the study
effect. No baseline differences mediated the study effect on
emergent anxiety (data available on request).
Discussion
The main finding of the present report is that incident
diagnostic outcomes of the CHR syndrome were specific
for psychosis, as compared with a comparison group of
help-seeking patients who answered CHR recruitment
efforts but did not meet CHR criteria. Psychosis was the
only incident disorder that significantly differed between
CHR and HSC patients in the merged sample or in either
study; nonpsychotic disorders emerged in CHR patients
at fairly low rates that were no higher than those in HSC
patients. We also note, in the merged sample, that psychosis was significantly more likely than most incident nonpsychotic disorders among CHR patients and that it was
significantly less likely than most incident nonpsychotic
disorders among HSC patients.
Similar specificity of psychotic outcomes has also been
observed in other studies of at-risk cohorts. A recent

meta-analysis of 6 population-based studies of mostly
adolescents and young adults showed that persons who
reported subthreshold psychotic experiences developed
psychotic clinical outcomes with a relative risk of 3.5, while
nonpsychotic clinical outcomes developed with a relative
risk of 1.4).44 Our findings are also similar to those recently
reported from a Melbourne CHR cohort,27 where psychosis emerged in 27.3% of the total sample (compared with
our merged sample 19.6%, figure 1), depression emerged
in approximately 7.3% (compared with 4.4%), and anxiety
disorder emerged in 13.9% (compared with 5.2%).
As noted, the similar rates of emergent nonpsychotic
disorders across the CHR and HSC groups were fairly
low (supplementary table 2). On an annualized basis,
these low rates are, however, generally higher than incident rates of nonpsychotic disorders in population-based
studies of adolescents and young adults,45–54 consistent
with CHR and HSC patients representing selected helpseeking clinical samples. By contrast, annualized rates of
emergent depression or anxiety in the CHR group were
lower than in population-based studies of adolescents or
young adults at risk for depression because of subsyndromal depressive symptoms52,55,56 (but see Jonsson U
and colleagues53) or at risk for anxiety disorder because
of subsyndromal anxiety.54 Rates of emergent depression
or anxiety in our CHR group were also lower than those
in clinical samples randomized into selective or indicated
prevention study control groups.57–73
Another important finding relates to study differences observed. Rates of emergent psychosis were lower
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in PREDICT than in the NAPLS-1, and specificity of
the emergent psychosis outcome was partially related to
this difference. In PREDICT this rate within the CHR
patient group did not differ significantly from that for
most incident nonpsychotic disorder groups (supplementary table 3); however, psychosis remained the only
emergent disorder that was significantly more likely in
CHR patients than in HSC patients (table 2). Analyses
indicated the study difference on emergent psychosis was partly accounted for by lower baseline severity
of PREDICT CHR patients on several measures. The
duration of the CHR syndrome, associated in previous
samples with baseline functioning74 and conversion,75
may have shorter in PREDICT as well, although these
data were not collected systematically in NAPLS-1. It is
possible that the PREDICT exclusion antipsychotics led
some severely ill or long duration CHR patients not to
contact us. Alternatively, when a CHR clinic first opens
more severely ill or longer duration patients may be preferentially sampled initially, removing them from subsequent sampling. Further work on prognostic variables in
relation to a general lowering of conversion rates in CHR
samples in recent years75 is indicated.
Limitations
The requirement for DSM-IV structured diagnostic
interview completion in the present report led to selection
of patient subsamples in both studies. The CHR rate of
emergent psychosis in the current subsample (NAPLS-1
24.2%, PREDICT 12.6%, table 2) is somewhat lower than
the raw conversion rates in the full sample (NAPLS-1
29.4%25 PREDICT 19.3%). These differences are largely
due to conversions recorded after the last DSM-IV diagnostic interview in both studies that were not counted
as cases of incident psychosis in the present analyses.
The structured interview completion requirement also
selected for a CHR sample of somewhat lower clinical
severity on several measures, especially in NAPLS-1 (see
full sample25) but also in PREDICT, and also to higher
rates of baseline antipsychotic in NAPLS-1 (see full
sample42).
Another limitation is the different rates of incident
anxiety disorder in PREDICT vs NAPLS-1. Baseline
rates of anxiety disorder were similar in the 2 studies
(table 1), and differences between studies on other measures did not account for the incident anxiety differences.
Because NAPLS-1 data were collected in independent
protocols,30 structured interviews for DSM-IV disorders
were not standardized across sites, and there are no fields
in the database to identify which interviews were used in
which patients. Thus, we cannot determine whether incident anxiety differences relate to interview differences.
A third limitation concerns sample size. Although our
combined samples were relatively large, samples in the
sensitivity analyses, and particularly in analyses excluding
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patients with any baseline affective or anxiety disorder,
were smaller (supplementary tables 1 and 2). In the analyses with the smallest sample sizes, statistical power was
sufficient to detect the emergence of any nonpsychotic
disorder as significantly different between groups if the
effect size was medium (as large as 0.4676). The main findings still seem convincing, however, since the observed
CHR vs HSC effect size for any nonpsychotic disorder
was very small at 0.05 (supplementary table 2) and the
large effect size for psychosis (1.02) led to sufficient power
to detect the CHR vs HSC difference as statistically significant despite the analyses with smaller sample sizes
(supplementary table 1).
A fourth limitation is that SIPS versions varied across
site and over time in the NAPLS-1 sample and between
NAPLS-1 and PREDICT. This variation is unlikely to
have seriously influenced study conclusions, because the
primary changes in the SIPS during this period involved
adding explicit ratings of symptom qualifiers that had
previously been included as free text fields, and thus the
definitions of CHR were unchanged.77
A final area of limitation involves the HSC patients.
While this group offers advantages as a comparison
group in that their recruitment was identical to that CHR
patients, the distinction between groups is that CHR
patients did, and HSC patients did not, meet criteria for
a current CHR syndrome. Unfortunately neither study
permitted structured determination of whether HSC subjects had ever met CHR syndrome criteria.78 Future studies should compare emergent outcomes between CHR
cases and age-matched psychiatric patients who never
met CHR criteria.
Conclusion
The clinical high-risk syndrome is unusual as a research
diagnostic entity in that it specifies risk for a future disorder. Its utility as a research diagnostic entity thus depends
in large part upon whether it can indeed predict increased
likelihood of conversion to psychosis and whether it can
do so with specificity relative to other incident disorders.
In our 2 samples the differential risk for developing psychosis when compared with help-seeking comparison
patients was substantial and contrasted sharply with no
observed difference in risk for bipolar disorder, nonbipolar mood disorder, and anxiety disorder. Risk for emergent nonpsychotic disorders was fairly low and lower
than that reported in previous studies selecting specifically for risk of affective or anxiety disorders. We interpret these findings to indicate that the CHR syndrome
does not identify patients at a globally increased risk for
psychopathology, but instead points towards a specific
risk for psychosis, at least in these samples.
Although our data indicate that the CHR criteria identify patients at specific risk for psychosis, it should also
be noted that nonpsychotic disorders did emerge in CHR
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patients, just as they did in non-CHR patients and at
comparable rates, and that these emergent nonpsychotic
disorders represent important clinical prevention targets
in both CHR and non-CHR patients.
Our findings suggest that the CHR syndrome does
offer a specific marker for use in research on predictors and mechanisms of developing psychosis and, in
addition, suggest a number of future directions. In the
research arena, the CHR syndrome may represent a fairly
late stage in the development of frank disorder,18,79–81 and
the specificity of diagnostic outcome for patients at an
earlier stage of psychotic illness should be investigated.
Additional population-based studies that examine markers of risk for multiple disorders and their relation to
multiple diagnostic outcomes would be most welcome. In
the clinical arena intervention studies should investigate
whether existing treatments differentially prevent specific
diagnostic outcomes, whether prevention specificity varies by illness stage, and whether new treatments that target specific outcomes can be developed.
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